UPDATE: Bank of America Raises PO to $99 on Amgen After Omontys Recall
Posted on February 25, 2013 at 09:44 AM EST
In a report published Monday, Bank of America reiterated a Neutral rating on Amgen (NASDAQ: AMGN ), and raised its price objective from $97 to $99. Bank of America wrote, "This weekend, AFFY/Takeda announced they were recalling all lots of their erythropoesis stimulating agent (ESA) Omontys from the market due